GALT Galectin Therapeutics Inc.

+0.05  (+1%)
Previous Close 3.92
Open 3.93
Price To Book 49.62
Market Cap 222,297,812
Shares 55,994,411
Volume 184,971
Short Ratio
Av. Daily Volume 365,279

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated during fall of 2019 with top-line data due 4Q 2022.
Non-alcoholic steatohepatitis (NASH) with cirrhosis
Phase 1b data released September 20, 2018. ORR 50%.
GR-MD-02 and pembrolizumab (KEYTRUDA)
Phase 2a interim data released May 2016
moderate-to-severe plaque psoriasis.

Latest News

  1. Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
  2. What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)?
  3. Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
  4. Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019
  5. Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
  6. Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
  7. Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
  8. Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
  9. Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248%
  10. Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
  11. Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
  12. Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
  13. Market Trends Toward New Normal in Infinera, Alliant Energy, Galectin Therapeutics, DexCom, Cutera, and Care — Emerging Consolidated Expectations, Analyst Ratings
  14. Galectin Therapeutics to Present at Berenberg NASH Day in New York
  15. Conatus (CNAT) Completes Enrollment in Phase II NASH Study
  16. Ascendis Pharma Files IND for Hypoparathyroidism Candidate
  17. Alkermes Sinks as FDA Refuses to Approve Depression Drug
  18. AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
  19. Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year?
  20. Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure